Principles of immunosuppression after liver transplantation Ewa Nowacka-Cieciura, Magdalena Durlik Medical Science Review - Hepatologia 2007; 7 9-17 aaICID: 485975
Article type: Review article
IC™ Value: 2.88
Abstract provided by Publisher
Liver transplantation is the definitive therapy for acute and chronic liver failure.
Long-term graft and recipient survival are excellent, reflecting the improved medical management and the development of more powerful immunosuppressive agents. The most commonly used immunosuppressive protocol in liver transplant recipients consists of tacrolimus, mycophenolate
mofetil and corticosteroids. Antibody-based induction therapy is uncommon; however it may facilitate steroid-free immunosuppression and delayed introduction of calcineurin inhibitor in the early posttransplant period. The incidence of acute rejection under standard immunosuppression is about 20%. The majority of rejection episodes are steroid sensitive. In case of steroid-resistant rejection antibody therapy is required.
There is an increasing trend toward individualization of therapy. The optimal treatment of HCV positive recipients remains the big challenge.